Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

New medicine

New treatment for chronic obstructive pulmonary disease

Olodaterol, a once-daily long acting β2-agonist inhaler, has been launched in the UK for chronic obstructive pulmonary disease.

Launch of new treatment for chronic obstructive pulmonary disease (COPD)


Sufferers of chronic obstructive pulmonary disease have a new drug to aid treatment

Olodaterol, a once-daily long acting beta2 agonist (LABA) inhaler, has been launched in the UK as an additional treatment option for chronic obstructive pulmonary disease (COPD).

The treatment is indicated as a maintenance bronchodilator treatment in patients with COPD. Improvement in lung function is comparable to formoterol and tiotropium, according to the summary of product characteristics.

“For people with mild or moderate COPD who remain breathless despite short-acting bronchodilators and who are not having frequent exacerbations, the LABAs offer an [equally] as effective alternative to the long-acting muscarinic antagonists such as tiotropium,” says Anna Murphy, consultant respiratory pharmacist at University Hospitals of Leicester NHS Trust.

A number of LABAs used for COPD already exist on the market, including formoterol, indacterol and vilanterol.

It is essential to confirm a diagnosis of COPD prior to starting LABA treatment without an inhaled corticosteroid because, for asthmatic patients, this regimen carries an increased risk of death, she added.

The most common adverse events associated with olodaterol include nasopharyngitis, dizziness, hypertension, rash and arthralgia.

Olodaterol is being marketed by Boehringer Ingelheim as Striverdi Respimat. The company is also seeking marketing approval for a once-daily fixed-dose combination inhaler of olodaterol plus tiotropium as a maintenance treatment for patients with COPD.

 Factfile: Product details
 Action: long acting betaagonist
 Dose: 5mg per day taken as two puffs via an inhaler once daily
 Legal category: Prescription only medicine
 NHS list price: one inhaler and 60 puff cartridge (30 doses) £26.35

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20065976

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.